Moderna (MRNA) Cash from Financing Activities (2018 - 2026)

Moderna has reported Cash from Financing Activities for 9 years, with the latest figure at $14.0 million in Q2 2026.

• Cash from Financing Activities for Q2 2026 came in at $14.0 million, up 55.56% year-over-year; the trailing twelve-month figure through Jun 2026 was $611.0 million (up 2809.52% YoY), and the FY2025 annual result was $593.0 million, up 958.93% from the prior year.
• Cash from Financing Activities declined to $14.0 million in Q2 2026, from $17.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $581.0 million in Q4 2025 and troughed at -$1.3 billion in Q2 2022.
• A 5-year average of -$230.3 million and a median of -$2.0 million in 2024 frame the typical range for Cash from Financing Activities.
• The widest annual swing landed in 2022, when Cash from Financing Activities plunged 51950.0%; it then jumped 19466.67% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$438.0 million in 2022, then jumped by 75.11% to -$109.0 million in 2023, then surged by 97.25% to -$3.0 million in 2024, then jumped by 19466.67% to $581.0 million in 2025, then slumped by 97.59% to $14.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $14.0 million in Q2 2026, $17.0 million in Q1 2026, and $581.0 million in Q4 2025.